Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.73 |
| ▸ | DRD1 | P21728 | 6/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.73 |
| ▸ | HTR2A | P28223 | 5/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.73 |
| ▸ | HTR2C | P28335 | 4/20 | 0.73 |
| ▸ | HTR2B | P41595 | 4/20 | 0.73 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.73 |
| ▸ | HTR6 | P50406 | 2/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.73 |
| ▸ | HTR1A | P08908 | 6/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metopimazine SCHEMBL30038347 | 1.00 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL29462317 | 1.00 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL22645258 | 0.98 | DRD3 (0.96) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL22645257 | 0.97 | DRD3 (0.95) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL13724685 | 0.93 | DRD3 (0.87) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL24570751 | 0.93 | DRD3 (0.86) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL15857644 | 0.91 | DRD2 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL30467248 | 0.87 | DRD2 (0.79) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL15847810 | 0.87 | DRD2 (0.79) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL21473954 | 0.86 | DRD2 (0.79) | DRD3DRD2HRH1SLC6A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3285 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122610-A1 | THERAPEUTIC COMBINATIONS AND METHODS FOR 5-HT3 RECEPTOR MODULATORS IN TREATING VARIOUS DISORDERS | SEROTONIX LLC (US) | 2025-06-12 | — | — | WO | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| US-20240156832-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | NEUROGASTRX, INC. | 2024-05-16 | — | — | US | claimed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| US-11834445-B2 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2023-12-05 | — | — | US | claimed |
| EP-4271385-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | Neurogastrx, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| US-20230142366-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. | 2023-05-11 | — | — | US | claimed |
| WO-2023049482-A1 | METHODS OF TREATING RESTRICTIVE EATING DISORDERS | ARVID THERAPEUTICS (US) | 2023-03-30 | — | — | WO | claimed |
| US-20230086867-A1 | POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. | 2023-03-23 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-6121276-A | ORALLY ADMINISTERING DSAGE OF APOMORPHINE TOGETHER WITH ANTIEMETIC PRIOR TO INTERCOURSE; SIDE EFFECT REDUCTION | PENTECH PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000035457-A1 | USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN MALES | ABBOTT LABORATORIES (US) | 2000-06-22 | — | — | WO | claimed |
| WO-1999066916-A1 | APOMORPHINE-CONTAINING DOSAGE FORMS FOR AMELIORATING MALE ERECTILE DYSFUNCTION | PENTECH PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| CN-1203527-A | Stable freeze-dried pharmaceutical formulation | SANOFI SA (FR) | 1998-12-30 | — | — | CN | claimed |
| EP-0858325-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1998-08-19 | — | — | EP | claimed |
| WO-1997017064-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1997-05-15 | — | — | WO | claimed |
| EP-0123585-B1 | TRANSDERMAL DRUG FORM | RHONE-POULENC SANTE (FR) | 1988-08-31 | — | — | EP | claimed |
| US-4746509-A | DISPERSION IN FILM-FORMING POLYMER | RHONE-POULENC SANTE (FR) | 1988-05-24 | — | — | US | claimed |
| EP-0123585-A2 | Transdermal drug form | RHONE-POULENC SANTE (FR) | 1984-10-31 | — | — | EP | claimed |